InnoCare Pharma Limited Overview
Get informed when a big investor buys or sells
+ Follow17.61%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
InnoCare Pharma Limited (INCPF) currently reports a ROE of 17.61%. That is above the Healthcare sector average of -75.84%. Use the charts on this page to explore InnoCare Pharma Limited's ROE history and peer comparisons.
InnoCare Pharma Limited's ROE of 17.61% is higher than the Healthcare sector average of -75.84%. That is roughly 123.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but InnoCare Pharma Limited's current 17.61% should be judged against Healthcare norms (sector average: -75.84%) and against INCPF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 17.61%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.84%. From there, open related valuation or income-statement pages for InnoCare Pharma Limited, and consider following INCPF for alerts when major investors trade the stock.
InnoCare Pharma Limited is classified in the Healthcare sector. On ROE, it currently shows 17.61% versus a sector average near -75.84%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing INCPF with unrelated industries.
